We take risks and challenge the status quo because disease must be fought with unexpected practice.
Unlike traditional therapeutic approaches that target growth factors in their active states, Scholar Rock uses its technology platform and structural insights to discover new medicines designed to selectively target the precursor, or inactive, forms of growth factors with the aim of avoiding toxicity and improving efficacy.Learn About Our Science
Scholar Rock works across therapeutic areas and shines new light on the overlooked to better target disease.
Our growing team is replete with good people who eat, sleep, and breathe good science. We promote a spirit of inquiry outside one’s traditional expertise to uncover enlightened solutions for patients.
Spinal Muscular Atrophy
November 15, 2022
Scholar Rock Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
November 14, 2022
Scholar Rock Reports Third Quarter 2022 Financial Results and Highlights Business Progress
November 10, 2022
Recent Phase 1 DRAGON Data Show SRK-181 Continues to be Well Tolerated with Early Indications of Efficacy